|
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Juno Therapeutics; Merck; Novartis; Takeda |
Research Funding - Bristol-Myers Squibb; Celgene; Takeda |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda |
Research Funding - Amgen; Celgene; Daiichi Sankyo; GlaxoSmithKline; Janssen; Takeda |
|
|
Consulting or Advisory Role - Amgen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Oncopeptides; Spectrum Pharmaceuticals; Takeda |
Research Funding - Amgen (Inst); Janssen Oncology (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Consulting or Advisory Role - Amgen; Antengene; Bristol-Myers Squibb; Celgene; Genzyme; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Novartis; OncoPeptides; Seagen; Secura Bio; Takeda |
Research Funding - Amgen; Celgene; Janssen; Novartis; Pharmacyclics; Seagen; Takeda |
|
|
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Sanofi (Inst); Seagen (Inst) |
Patents, Royalties, Other Intellectual Property - PSA vaccine patent |
|
|
Research Funding - Cellectar |
|
|
|
Consulting or Advisory Role - Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Research Funding - Amgen (Inst); Celgene (Inst); Janssen (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Celgene; GlaxoSmithKline; Janssen; Novartis; Oncopeptides; TeneoBio |
|
|
Employment - GlaxoSmithKline |
|
Stock and Other Ownership Interests - GlaxoSmithKline; ImmunoGen |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline (Inst) |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Janssen Oncology; Kite, a Gilead company; Oncopeptides; Seagen; Takeda |
Research Funding - Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome |
Expert Testimony - Janssen Oncology |
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Takeda |